Parexel International Corp. (NSDQ:PRXL) expanded its footprint in Asia, opening new offices in Chengdu and Guangzhou, China.
The Waltham, Mass.-based clinical research organization established the new locations to help grow its clinical development and regulatory consulting capabilities in the country and the Asia-Pacific region, according to a press release.
Parexel currently has offices in Beijing, Shanghai, Kowloon and Hong Kong, in addition to 14 offices in neighboring countries including Australia, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan and Thailand.
In February of this year, Parexel expanded its clinical testing facilities in South Africa.
The company’s third-quarter profits fell 10 percent, despite revenues of $344.4 million for the three months ended March 31, a 10.8 percent improvement over the $311.0 million recorded during the same period last year.